Pediatric Acute Lymphoblastic Leukemia

3

Review clinical trials related to Pediatric Acute Lymphoblastic Leukemia. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Weight Gain in Pediatric Leukemia Survivors

This is a trial assessing the efficacy of two weight maintenance programs for children with acute lymphoblastic leukemia (ALL) and the patients' caregivers. Patients and their caregivers will be randomized 1:1 to Arm A, a non-intensive educational intervention using National Institute of Health (NIH) Educational Resources (We Can! for children 8-13 and Take Charge of Your Health for teenagers 14-18), or Arm B, a Modified Guided Self-Help Family Intervention for Leukemia patients (mL-GSH). Outcomes will be assessed through activity trackers, obesity biometrics, and nutrition and physical activity assessments.

Participants needed: 80
Trial details
Age: 6+Biological sex: AllType: InterventionalSponsor: Washington University School of MedicineUpdated: Apr 28, 2026Locations: 1
Eligibility criteria

Must have a diagnosis of ALL (T or B cell). [+13]

Status: Recruiting

INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)

This is a multicenter, experimental preclinical study conducted on primary samples from patients diagnosed with hematological or solid neoplasms defined as high risk. The study will be prospective, based on the consecutive enrollment of eligible patients at each participating institution.

Participants needed: 300
Trial details
Age: 1+Biological sex: AllType: InterventionalSponsor: Azienda Ospedaliero-Universitaria di ParmaUpdated: Feb 17, 2026Locations: 2
Eligibility criteria

Patients aged one year and over who are referred to the centres involved in the... [+3]

Patients younger than 1 year old [+1]

Status: Recruiting

Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia

* Clinical and genetic factors consistent with High risk : Induction → Consolidation 1. BM MRD \&lt; 0.01% : IM #1 → DI #1 → IM #2 → Maintenance 2. BM MRD ≥ 0.01% : IM #1 → DI #1 → IM #2 → DI #2 → Maintenance 3. BM MRD ≥ 0.01% after Consolidation <!-- --> 1. T cell ALL : Change to very high risk regimen 2. Pre-B ALL : IM #1 → Intensification 1. BM MRD \&lt; 0.01% after IM #1 : DI #1 → IM #2 → DI #2 → Maintenance 2. BM MRD ≥ 0.01% after IM #1 : Change to Very high risk regimen * Difference in the number of \&#39;interim maintenance(IM)\&#39; and \&#39;delayed intensification(DI)\&#39; is important for chemotherapies based on MRD.

Participants needed: 370
Trial details
Phase: Phase 2Age: 1-19Biological sex: AllType: InterventionalSponsor: Jae Wook LeeUpdated: Jun 8, 2025Locations: 7
Eligibility criteria

Age: 1year~19years of age at diagnosis [+4]

Patients with Burkitt leukemia/lymphoma or mature B-cell leukemia [+4]